Journal article icon

Journal article

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.

Abstract:

The safety and immunogenicity of a new candidate tuberculosis (TB) vaccine, FP85A was evaluated alone and in heterologous prime-boost regimes with another candidate TB vaccine, MVA85A. This was an open label, non-controlled, non-randomized Phase I clinical trial. Healthy previously BCG-vaccinated adult subjects were enrolled sequentially into three groups and vaccinated with FP85A alone, or both FP85A and MVA85A, with a four week interval between vaccinations. Passive and active data on adver...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.4161/hv.22464

Authors


Journal:
Human vaccines and immunotherapeutics More from this journal
Volume:
9
Issue:
1
Pages:
50-62
Publication date:
2013-01-01
DOI:
EISSN:
2164-554X
ISSN:
2164-5515
Language:
English
Keywords:
Pubs id:
pubs:358666
UUID:
uuid:e951b6e4-767b-47fa-9d2c-ce735513856f
Local pid:
pubs:358666
Source identifiers:
358666
Deposit date:
2013-11-17

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP